Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01021800

Acronym

SYSTHER

Enrollment

Registered

2009-11-30

Start date

2009-04-30

Completion date

2012-12-31

Last updated

2010-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Tubular Adenocarcinoma

Keywords

Pancreatic tubular adenocarcinoma adjuvant setting

Brief summary

Interventional study of modulation of immune response in patients with pancreatic tubular adenocarcinoma after resection and gemcitabine treatment. When included, patients are pre-treated with moderate doses of cyclophosphamide. Then infusions of allogeneic mononuclear cells are given.

Interventions

BIOLOGICALMIS

Cell infusion

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* ECOG performance status 0-2 at the time of inclusion * Following R0 or R1 pancreatic tubular adenocarcinoma resection and adjuvant gemcitabine treatment

Exclusion criteria

* Pregnancy * Less than 3 mths expected survival * Serious comorbidity * Age above 70 yrs

Design outcomes

Primary

Measure	Time frame
PROGRESSION FREE SURVIVAL	1 YEAR

Countries

Slovenia

Contacts

Primary ContactBorut Stabuc, MD PhD

borut.stabuc@kclj.si+38615222210

Backup ContactLojze Smid, MD

lojze.smid.jr@mf.uni-lj.si

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026